The identification of antigens associated with tumor destruction is a major goal of cancer immunology. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF) generates potent, specific, and long-lasting anti-tumor immunity in murine models through improved tumor antigen presentation by dendritic cells and macrophages. Two phase I clinical trials evaluating this immunization strategy in patients with disseminated melanoma revealed the consistent induction in distant metastases of dense T and B cell infiltrates that effectuated substantial tumor necrosis and fibrosis. The ATP6S1 subunit of the vacuolar-ATPase complex, the putative opioid growth factor receptor OGFR, and the melanoma inhibitor of apoptosis protein (ML-IAP) were identified as target antigens for antibodies or T cells in some long-term responding patients. In a pilot study of previously vaccinated patients, the subsequent administration of a humanized blocking antibody against cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) stimulated additional tumor destruction with lymphocyte and granulocyte infiltrates, albeit with the development of T cell reactivity to normal melanocytes. These findings motivated larger clinical trials testing autologous, GM-CSF secreting melanoma cell vaccines followed by CTLA-4 antibody blockade. The analysis of clinical samples obtained from these studies should help elucidate the mechanisms and targets of immune-mediated tumor destruction.
The specific aims of this proposal are to: 1. Identify antigens eliciting humoral responses associated with immune-mediated tumor destruction 2. Determine whether CD4+ and CD8+ T cell responses are coordinately stimulated against these antigens 3. Determine whether altered expression or mutation contributes to the immunogenicity of these antigens 4. Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA111506-02
Application #
7005442
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Howcroft, Thomas K
Project Start
2005-01-05
Project End
2009-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
2
Fiscal Year
2006
Total Cost
$302,403
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Goldberg, John M; Fisher, David E; Demetri, George D et al. (2015) Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res 21:3178-86
Schoenfeld, Jonathan D; Dranoff, Glenn (2011) Anti-angiogenesis immunotherapy. Hum Vaccin 7:976-81
Schoenfeld, Jonathan; Jinushi, Masahisa; Nakazaki, Yukoh et al. (2010) Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res 70:10150-60
Ho, Vincent T; Vanneman, Matthew; Kim, Haesook et al. (2009) Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 106:15825-30
Jinushi, Masahisa; Nakazaki, Yukoh; Carrasco, Daniel R et al. (2008) Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res 68:8889-98
Hodi, F Stephen; Butler, Marcus; Oble, Darryl A et al. (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105:3005-10
Jinushi, Masahisa; Vanneman, Matthew; Munshi, Nikhil C et al. (2008) MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 105:1285-90
Jinushi, Masahisa; Hodi, F Stephen; Dranoff, Glenn (2006) Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 103:9190-5
Dranoff, Glenn (2005) The therapeutic implications of intratumoral regulatory T cells. Clin Cancer Res 11:8226-9